Q/C TECHNOLOGIES, INC. (QCLS) Form 8-K — Nov 20, 2026
On November 20, 2026, Q/C Technologies entered into an Omnibus Amendment Agreement with PharmaCyte Biotech, Inc., which holds at least a majority of both the Series G and Series H convertible preferred stock and thereby constitutes the Required Holders under each certificate of designations. The agreement amended both certificates of designations and the Series G Long-Term Warrants, raising PharmaCyte's beneficial ownership limitation on conversions and warrant exercises to 49.99% of outstanding common stock, versus 4.99% for other holders. Amendments became effective upon filing with the Delaware Secretary of State on November 20, 2026.
Key figures
- Series h maturity new
- 2027-09-02
- Series h maturity old
- 2027-03-02
- Series g authorized shares
- 12826273
- Series h authorized shares
- 7000
- Pharmacyte beneficial ownership cap
- 49.99%
- Series g long term warrant term years
- 5
- Other holders beneficial ownership cap
- 4.99%
- Series g short term warrant term months
- 18
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.